biosimilars

Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Novartis
Biocon
drug development
biosimilars
Flag link:
Novartis aims for US approval of Humira biosimilar
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Novartis
Humira
biosimilars
AbbVie
Sandoz
Flag link:
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Fierce Pharma
Roche
Pharma CEOs
Severin Schwan
biosimilars
Herceptin
Rituxan
Avastin
Flag link:
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis
Flag link:
Boasting a late-stage Botox me-too, Evolus files for $75M IPO
Boasting a late-stage Botox me-too, Evolus files for $75M IPO
Endpoints
Evolus
Botox
Allergan
IPOs
DWP-450
biosimilars
Flag link:
Top 10 stories that had pharma execs talking
Top 10 stories that had pharma execs talking
Biopharma Dive
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Flag link:
Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Drug Delivery Business News
Mylan Labs
Momenta Pharmaceuticals
Regeneron
Eylea
biosimilars
diabetic macular edema
wet age-related macular degeneration
M710
Flag link:
Here's How AbbVie Inc. Crushed It in 2017
Here's How AbbVie Inc. Crushed It in 2017
Yahoo/Motley Fool
AbbVie
biosimilars
Humira
Imbruvica
Flag link:
Biopharma trends to watch in 2018
Biopharma trends to watch in 2018
BioPharma Dive
drug pricing
M&A
gene therapy
biosimilars
opioids
ophthalmology
Flag link:
Fresenius closer and closer to marketing biosimilars
Fresenius closer and closer to marketing biosimilars
GoinPharma
Fresenius
biosimilars
Flag link:
The 2018 biosimilar litigation landscape: A primer
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Flag link:
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
RAPS.org
Pfizer
biosimilars
Remicade
Ixifi
Inflectra
JNJ
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
AbbVie Makes Progress on Quest to Diversify
AbbVie Makes Progress on Quest to Diversify
Motley Fool
AbbVie
biosimilars
Roche
Venclexta
Flag link:
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
Cafepharma Message Boards
Pfizer
biosimilars
Inflectra
Remicade
JNJ
Flag link:
Roche's Fight With Pfizer May Be Just The Beginning
Roche's Fight With Pfizer May Be Just The Beginning
Forbes
Roche
Pfizer
Herceptin
biosimilars
cancer
Avastin
Rituxan
Flag link:
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Novartis
Neulasta
biosimilars
Amgen
Sandoz
FDA
Flag link:
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
JD Supra
Pfizer
JNJ
Remicade
biosimilars
anticompetitive practices
Celltrion
Flag link:
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Fierce Pharma
JNJ
biosimilars
Remicade
Europe
anti-TNF
Flag link:
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin
RAPS.org
FDA
biosimilars
Herceptin
Ogivri
Mylan Labs
Biocon
Flag link:

Pages